vs
Side-by-side financial comparison of LCNB CORP (LCNB) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 23.7%, a 42.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 5.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 15.7%).
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
LCNB vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.9M | $18.6M |
| Net Profit | $5.7M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 29.2% | 56.3% |
| Net Margin | 23.7% | 65.7% |
| Revenue YoY | 5.1% | 1808.5% |
| Net Profit YoY | -7.6% | 376.5% |
| EPS (diluted) | $0.40 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.9M | $18.6M | ||
| Q3 25 | $23.8M | $334.0K | ||
| Q2 25 | $22.8M | $1.4M | ||
| Q1 25 | $21.5M | $257.0K | ||
| Q4 24 | $22.7M | $977.0K | ||
| Q3 24 | $21.4M | $660.0K | ||
| Q2 24 | $19.3M | $736.0K | ||
| Q1 24 | $17.8M | $1.4M |
| Q4 25 | $5.7M | $12.3M | ||
| Q3 25 | $6.9M | $-8.6M | ||
| Q2 25 | $5.9M | $-6.9M | ||
| Q1 25 | $4.6M | $-5.4M | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $4.5M | $-2.8M | ||
| Q2 24 | $925.0K | $-14.5M | ||
| Q1 24 | $1.9M | $411.0K |
| Q4 25 | 29.2% | 56.3% | ||
| Q3 25 | 35.6% | -2516.5% | ||
| Q2 25 | 31.6% | -701.0% | ||
| Q1 25 | 25.6% | -3350.2% | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 24.9% | -1563.6% | ||
| Q2 24 | 4.9% | -1255.0% | ||
| Q1 24 | 12.5% | -692.5% |
| Q4 25 | 23.7% | 65.7% | ||
| Q3 25 | 29.1% | -2572.2% | ||
| Q2 25 | 26.0% | -504.8% | ||
| Q1 25 | 21.4% | -2097.7% | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 21.2% | -425.5% | ||
| Q2 24 | 4.8% | -1964.4% | ||
| Q1 24 | 10.7% | 29.9% |
| Q4 25 | $0.40 | $0.25 | ||
| Q3 25 | $0.49 | $-0.17 | ||
| Q2 25 | $0.41 | $-0.14 | ||
| Q1 25 | $0.33 | $-0.11 | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.31 | $-0.06 | ||
| Q2 24 | $0.07 | $-0.30 | ||
| Q1 24 | $0.15 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.6M | $40.0M |
| Total DebtLower is stronger | $104.4M | — |
| Stockholders' EquityBook value | $273.9M | $49.4M |
| Total Assets | $2.2B | $59.0M |
| Debt / EquityLower = less leverage | 0.38× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.6M | $40.0M | ||
| Q3 25 | $35.9M | $37.9M | ||
| Q2 25 | $49.8M | $44.8M | ||
| Q1 25 | $37.7M | $40.6M | ||
| Q4 24 | $35.7M | $59.3M | ||
| Q3 24 | $39.4M | $68.8M | ||
| Q2 24 | $34.9M | $73.0M | ||
| Q1 24 | $33.0M | $80.2M |
| Q4 25 | $104.4M | — | ||
| Q3 25 | $104.7M | — | ||
| Q2 25 | $105.0M | — | ||
| Q1 25 | $104.6M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $155.7M | — | ||
| Q2 24 | $162.2M | — | ||
| Q1 24 | $162.6M | — |
| Q4 25 | $273.9M | $49.4M | ||
| Q3 25 | $269.9M | $36.4M | ||
| Q2 25 | $263.5M | $44.5M | ||
| Q1 25 | $258.7M | $50.5M | ||
| Q4 24 | $253.0M | $55.1M | ||
| Q3 24 | $253.2M | $58.5M | ||
| Q2 24 | $245.2M | $60.4M | ||
| Q1 24 | $233.7M | $74.1M |
| Q4 25 | $2.2B | $59.0M | ||
| Q3 25 | $2.2B | $51.1M | ||
| Q2 25 | $2.3B | $60.7M | ||
| Q1 25 | $2.3B | $67.9M | ||
| Q4 24 | $2.3B | $90.6M | ||
| Q3 24 | $2.3B | $99.0M | ||
| Q2 24 | $2.4B | $107.8M | ||
| Q1 24 | $2.3B | $118.3M |
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.4M | $18.4M |
| Free Cash FlowOCF − Capex | $33.4M | — |
| FCF MarginFCF / Revenue | 140.2% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | 6.08× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $54.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.4M | $18.4M | ||
| Q3 25 | $14.0M | $-8.7M | ||
| Q2 25 | $5.5M | $-7.5M | ||
| Q1 25 | $2.2M | $-7.5M | ||
| Q4 24 | $93.2M | $-24.0M | ||
| Q3 24 | $11.9M | $765.0K | ||
| Q2 24 | $54.9M | $-10.9M | ||
| Q1 24 | $-11.9M | $-4.0M |
| Q4 25 | $33.4M | — | ||
| Q3 25 | $13.7M | — | ||
| Q2 25 | $5.2M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $89.4M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $53.8M | — | ||
| Q1 24 | $-12.8M | — |
| Q4 25 | 140.2% | — | ||
| Q3 25 | 57.4% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 394.0% | — | ||
| Q3 24 | 49.0% | — | ||
| Q2 24 | 278.6% | — | ||
| Q1 24 | -71.8% | — |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 4.8% | — |
| Q4 25 | 6.08× | 1.50× | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 15.23× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 59.35× | — | ||
| Q1 24 | -6.24× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LCNB
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
